Brief: Mustang Bio Announces FDA Acceptance Of IND Application For MB-109

Mustang Bio

26/10/2023 15:13

Oct 26 (Reuters) - Fortress Biotech Inc  FBIO.O :
    * MUSTANG BIO ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION
FOR
MB-109, A NOVEL COMBINATION OF MB-101 (IL13RΑ2‐TARGETED CAR-T
CELL THERAPY) AND MB-108 (HSV-1 ONCOLYTIC VIRUS), FOR THE
TREATMENT OF RECURRENT GLIOBLASTOMA AND HIGH-GRADE ASTROCYTOMA
    * MUSTANG BIO INC - PHASE 1 STUDY EXPECTED TO BEGIN
ENROLLING
PATIENTS IN 2024
    * MUSTANG BIO- PHASE 1 STUDY WILL ASSESS SAFETY,
TOLERABILITY AND
EFFICACY OF MB-109 IN PATIENTS WITH RECURRENT GLIOBLASTOMA AND
HIGH-GRADE ASTROCYTOMA

Source text for Eikon:  ID:nGNX21qX0m 
Further company coverage:  FBIO.O 

 ((Reuters.Briefs@thomsonreuters.com))